Publications by authors named "Riho Klement"
Article Synopsis
- The EMPRISE study evaluated empagliflozin's effectiveness in reducing various health risks (including all-cause mortality and hospitalization for heart failure) compared to DPP-4 inhibitors in patients with type 2 diabetes across four Nordic countries.
- Using a noninterventional, multicountry cohort design and propensity score matching, the study analyzed data from 43,695 patients and employed Cox proportional hazards regression for risk assessment.
- Results indicated that patients starting empagliflozin had a significantly lower risk of all-cause mortality, hospitalization for heart failure, cardiovascular mortality, and end-stage renal disease, though no significant differences were found for stroke or myocardial infarction.
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia.
Cardiovasc Diabetol
August 2023
Article Synopsis
- - The study compares cardiovascular risks in patients with type 2 diabetes who started either empagliflozin or dipeptidyl peptidase-4 inhibitors (DPP-4i) across Europe and Asia, focusing on those with and without prior cardiovascular disease (CVD) or heart failure (HF).
- - Using data from over 85,000 matched patients and advanced statistical methods, the research found that empagliflozin users had a significantly lower risk of hospitalizations for heart failure, cardiovascular mortality, and strokes compared to DPP-4i users.
- - Overall, the findings indicate that empagliflozin offers protective cardiovascular benefits in diverse populations, regardless of their history of heart disease or heart
Background: Continued expansion of indications for sodium-glucose cotransporter-2 inhibitors increases importance of evaluating cardiovascular and kidney efficacy and safety of empagliflozin in patients with type 2 diabetes compared to similar therapies.
Methods: The EMPRISE Europe and Asia study is a non-interventional cohort study using data from 2014-2019 in seven European (Denmark, Finland, Germany, Norway, Spain, Sweden, United Kingdom) and four Asian (Israel, Japan, South Korea, Taiwan) countries. Patients with type 2 diabetes initiating empagliflozin were 1:1 propensity score matched to patients initiating dipeptidyl peptidase-4 inhibitors.
Aims/introduction: We investigated the utilization of healthcare resources in patients with type 2 diabetes treated with empagliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor, versus dipeptidyl peptidase-4 (DPP-4) inhibitors in clinical practice in Japan, South Korea, and Taiwan.
Materials And Methods: We analyzed the Japanese Medical Data Vision database (December 2014-April 2018), the South Korean National Health Information Database, and the Taiwanese National Health Insurance claims database (both May 2016-December 2017). Patients with type 2 diabetes starting empagliflozin, 10 or 25 mg, or a DPP-4 inhibitor were matched 1:1 via propensity scores (PS).
Aim: To evaluate the effectiveness of empagliflozin in clinical practice in East Asia in the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) East Asia study.
Materials And Methods: Data were obtained from the Medical Data Vision database (Japan), National Health Insurance Service database (South Korea) and National Health Insurance database (Taiwan). Patients aged ≥ 18 years with type 2 diabetes initiating empagliflozin or a dipeptidyl peptidase-4 (DPP-4) inhibitor were 1:1 propensity score (PS) matched into sequentially built cohorts of new users naïve to both drug classes.
Background: Previous studies reported no increase in the prevalence of adverse pregnancy outcomes after exposure to interferon-beta (IFN-beta). However, no study has investigated if the prevalence of these outcomes after IFN-beta exposure is modified by maternal and newborn characteristics. Our objective was to describe the stratified prevalence of adverse pregnancy outcomes among women with multiple sclerosis (MS) exposed only to IFN-beta or unexposed to any MS disease modifying drugs (MSDMDs).
View Article and Find Full Text PDFObjectives: We aimed to describe treatment patterns of chronic lymphocytic leukaemia (CLL) patients in routine practice settings, compare overall survival and time-to-next-treatment among patients treated in different time periods (2005-2008, 2009-2013, 2014-2015), and explore associated factors.
Methods: This retrospective cohort study included adult CLL patients from the Finnish Hematology Registry.
Results: In total, 124 and 64 CLL patients received first- and second-line treatments, respectively.